Chimeric antigen receptor (CAR)-NK cell therapy in gastrointestinal (GI) cancers; a new arena

IF 3.5 3区 生物学 Q3 CELL BIOLOGY
Ali G. Alkhathami , Abdulrahman T. Ahmed , Ahmed Hussn , S. RenukaJyothi. , Rajashree Panigrahi , Hussein Riyadh Abdul Kareem Al-Hetty , Hansi Negi , Pushkar Jassal , Fathi Jihad Hammady , Salah Abdulhadi Salih
{"title":"Chimeric antigen receptor (CAR)-NK cell therapy in gastrointestinal (GI) cancers; a new arena","authors":"Ali G. Alkhathami ,&nbsp;Abdulrahman T. Ahmed ,&nbsp;Ahmed Hussn ,&nbsp;S. RenukaJyothi. ,&nbsp;Rajashree Panigrahi ,&nbsp;Hussein Riyadh Abdul Kareem Al-Hetty ,&nbsp;Hansi Negi ,&nbsp;Pushkar Jassal ,&nbsp;Fathi Jihad Hammady ,&nbsp;Salah Abdulhadi Salih","doi":"10.1016/j.yexcr.2025.114683","DOIUrl":null,"url":null,"abstract":"<div><div>Tumor microenvironment (TME) is highly complex, and immune escape is a crucial characteristic of malignancies that promotes tumor development and spread. According to studies, the limited success achieved by T cell immunotherapy highlights the growing importance of other advanced immunotherapies, specifically those based on natural killer (NK) cells. Human NK cells are the primary innate immune cells that combat malignancies and exhibit significant diversity within the TME of gastrointestinal (GI) cancers. There is currently a growing interest in the advancement of chimeric antigen receptor (CAR)-engineered NK cells for GI cancer immunotherapy. The advantages of CAR-NK cells over CAR-T cells include enhanced safety, with minimal or no occurrence of cytokine release syndrome (CRS) and graft-versus-host disease (GVHD). Additionally, CAR-NK cells employ many methods to stimulate cytotoxic function and are very feasible for \"off-the-shelf\" manufacture. These effector cells can be genetically altered to specifically recognize different antigens, enhance their ability to multiply and survive in the body, increase their ability to enter GI cancers and overcome resistance in the tumor microenvironment. This ultimately leads to a desired anti-tumor response. Significantly, CAR-NK cells serve as antigen receptors for tumor-associated antigens (TAAs), effectively diverting NK cells and promoting tumor-related immunosurveillance. This study examines the advancements in the therapeutic capabilities of CAR-NK cells for treating GI cancers.</div></div>","PeriodicalId":12227,"journal":{"name":"Experimental cell research","volume":"450 2","pages":"Article 114683"},"PeriodicalIF":3.5000,"publicationDate":"2025-07-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Experimental cell research","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0014482725002836","RegionNum":3,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"CELL BIOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Tumor microenvironment (TME) is highly complex, and immune escape is a crucial characteristic of malignancies that promotes tumor development and spread. According to studies, the limited success achieved by T cell immunotherapy highlights the growing importance of other advanced immunotherapies, specifically those based on natural killer (NK) cells. Human NK cells are the primary innate immune cells that combat malignancies and exhibit significant diversity within the TME of gastrointestinal (GI) cancers. There is currently a growing interest in the advancement of chimeric antigen receptor (CAR)-engineered NK cells for GI cancer immunotherapy. The advantages of CAR-NK cells over CAR-T cells include enhanced safety, with minimal or no occurrence of cytokine release syndrome (CRS) and graft-versus-host disease (GVHD). Additionally, CAR-NK cells employ many methods to stimulate cytotoxic function and are very feasible for "off-the-shelf" manufacture. These effector cells can be genetically altered to specifically recognize different antigens, enhance their ability to multiply and survive in the body, increase their ability to enter GI cancers and overcome resistance in the tumor microenvironment. This ultimately leads to a desired anti-tumor response. Significantly, CAR-NK cells serve as antigen receptors for tumor-associated antigens (TAAs), effectively diverting NK cells and promoting tumor-related immunosurveillance. This study examines the advancements in the therapeutic capabilities of CAR-NK cells for treating GI cancers.
嵌合抗原受体(CAR)-NK细胞治疗胃肠道肿瘤一个新的竞技场。
肿瘤微环境(Tumor microenvironment, TME)高度复杂,免疫逃逸是恶性肿瘤的重要特征,促进肿瘤的发展和扩散。根据研究,T细胞免疫疗法取得的有限成功凸显了其他先进免疫疗法的重要性,特别是那些基于自然杀伤(NK)细胞的免疫疗法。人类NK细胞是对抗恶性肿瘤的主要先天免疫细胞,在胃肠道(GI)癌症的TME中表现出显著的多样性。目前,人们对嵌合抗原受体(CAR)工程NK细胞用于胃肠道肿瘤免疫治疗的进展越来越感兴趣。CAR-NK细胞相对于CAR-T细胞的优势包括安全性增强,很少或没有发生细胞因子释放综合征(CRS)和移植物抗宿主病(GVHD)。此外,CAR-NK细胞采用许多方法来刺激细胞毒性功能,并且非常适合“现成”制造。这些效应细胞可以通过基因改造特异性识别不同的抗原,增强其在体内繁殖和存活的能力,增加其进入胃肠道癌症的能力,并克服肿瘤微环境中的耐药性。这最终导致预期的抗肿瘤反应。值得注意的是,CAR-NK细胞作为肿瘤相关抗原(TAAs)的抗原受体,有效地转移NK细胞并促进肿瘤相关免疫监视。本研究探讨了CAR-NK细胞治疗胃肠道癌症的治疗能力的进展。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Experimental cell research
Experimental cell research 医学-细胞生物学
CiteScore
7.20
自引率
0.00%
发文量
295
审稿时长
30 days
期刊介绍: Our scope includes but is not limited to areas such as: Chromosome biology; Chromatin and epigenetics; DNA repair; Gene regulation; Nuclear import-export; RNA processing; Non-coding RNAs; Organelle biology; The cytoskeleton; Intracellular trafficking; Cell-cell and cell-matrix interactions; Cell motility and migration; Cell proliferation; Cellular differentiation; Signal transduction; Programmed cell death.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信